RxDoctor Payments Data

Eric Peterson, MD

Family Medicine · Boone, IANPI 1710955877

Payments from drug & device makers

$2,004in general payments, 2019–2025

Across 135 payments — averaging $14.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$269
  • Amgen$242
  • Novo Nordisk$239
  • Boehringer Ingelheim$186
  • Astellas Pharma US Inc$154
  • Johnson & Johnson$136
  • plus $779 from 17 others

What the payments were for

  • Food & beverage$1,91596%
  • Education$894%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,004 in reported general payments places this provider in the 85th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$15,287
Medicare patients
66
Services billed
185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban307$216,346
OzempicSemaglutide141$159,866
JardianceEmpagliflozin165$154,177
TrulicityDulaglutide89$91,978
XareltoRivaroxaban57$47,493
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr72$33,060
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$31,278
Tresiba Flextouch U-100Insulin Degludec34$22,750
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog34$16,832
Stiolto RespimatTiotropium Br/Olodaterol Hcl23$15,042
Lantus SolostarInsulin Glargine,hum.Rec.Anlog75$12,564
LinzessLinaclotide15$11,790
Combivent RespimatIpratropium/Albuterol Sulfate19$9,557
MyrbetriqMirabegron24$9,235
Spiriva RespimatTiotropium Bromide14$7,869

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$269$216,346307 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Combivent Respimat, Spiriva Respimat$186$186,645221 claims
Novo NordiskOzempic$239$159,866141 claims
Lilly USA, LLCTrulicity$106$91,97889 claims
GSKAnoro Ellipta, Trelegy Ellipta$29$64,338119 claims
Johnson & JohnsonXarelto$136$47,49357 claims
AbbVieLinzess$107$11,79015 claims
Astellas Pharma US IncMyrbetriq$154$9,23524 claims
Sanofi-aventis U.S. LLCLantus$105$4,07118 claims
AstraZenecaSymbicort$36$2,53211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Boone

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →